IN THE CLAIMS

Amended Claims

1. (Currently Amended) A compound of the formula (Ia), (Ib) or (Ic),



(Ia)



(Ib)



(Ic)



(I)

~~in which~~

~~A~~



~~or~~



R^1 is hydrogen, C_1-C_{20}-alkyl, C_2-C_{20}-alkenyl, C_2-C_{20}-alkynyl, cycloalkyl with three to eight ring carbon atoms, cycloalkenyl with three to eight ring carbon atoms, cycloalkylalkyl with five to six ring carbon atoms, aryl, heteroaryl, alkylaryl, alkylheteroaryl, arylalkyl, heteroarylalkyl, wherein R^1 is unsubstituted or substituted with at least one substituent chosen from R^6,

R^2 is C_1-C_{20}-alkyl, C_2-C_{20}-alkenyl, C_2-C_{20}-alkynyl, cycloalkyl with three to eight ring carbon atoms, cycloalkenyl with three to eight ring carbon atoms, cycloalkylalkyl with five to six ring carbon atoms, aryl, heteroaryl, alkylaryl, alkylheteroaryl, arylalkyl, or heteroaryalkyl wherein R^2 is unsubstituted or substituted with at least one substituent chosen from R^6,

$R^{2'}$ is C_2-C_{20}-alkenyl, C_2-C_{20}-alkynyl, cycloalkenyl with three to eight ring carbon atoms, cycloalkylalkyl with five to six ring carbon atoms, aryl, heteroaryl, alkylaryl, alkylheteroaryl, arylalkyl, or heteroaryalkyl wherein $R^{2'}$ is unsubstituted or substituted with at least one substituent chosen from R^6,

or R^1 and R^2, together with the nitrogen atom bearing them, form a 3-8-membered ring which may optionally comprises 0, 1 or 2 further heteroatoms chosen from N, O, and S, and wherein said 3-8-membered ring is unsubstituted or substituted by at least one substituent chosen from R^6,

R^3 is hydrogen, -CO-alkyl, -CO-alkylaryl, -CO-alkylheteroaryl, -CO-aryl, or -CO-heteroaryl,

R^4 is C_1-C_{20}-alkyl, C_2-C_{20}-alkenyl, C_2-C_{20}-alkynyl, cycloalkyl with three to eight ring carbon atoms, cycloalkenyl with three to eight ring carbon atoms, cycloalkylalkyl with five to six ring carbon atoms, aryl, heteroaryl, alkylaryl, alkylheteroaryl, arylalkyl, heteroarylalkyl, -CO-O-alkyl, -CO-O-aryl, -CO-O-heteroaryl, -CO-alkyl, -CO-aryl or –CO-heteroaryl wherein R^4 is unsubstituted or substituted with at least one substituent chosen from R^7,

$R^{4'}$ is C_2-C_{20}-alkenyl, C_2-C_{20}-alkynyl, cycloalkyl with three to eight ring carbon atoms, cycloalkenyl with three to eight ring carbon atoms, cycloalkylalkyl with five to six ring carbon atoms, heteroaryl, alkylheteroaryl, heteroarylalkyl, -CO-O-alkyl, -CO-O-aryl, -CO-O-heteroaryl, -CO-O-aryl or -CO-O-heteroaryl wherein $R^{4'}$ is unsubstituted or substituted with at least one substituent chosen from R^7,

R^5 is hydrogen, -CO-alkyl, -CO-alkylaryl, -CO-alkylheteroaryl, -CO-aryl, or CO-heteroaryl,

R^6 is -F, -OH, -O-(C_1-C_{10})-alkyl, -O-phenyl, -O-CO-(C_1-C_{10})-alkyl, -O-CO-aryl, -O-CO-heteroaryl, -NR^8R^9, oxo, phenyl, -CO-(C_1-C_5)-alkyl, -CF_3, -CN, -$CONR^8R^9$, -COOH, -CO-O-(C_1-C_5)-alkyl, -CO-O-aryl, -CO-O-heteroaryl, -$S(O)_n$-(C_1-C_5)-alkyl, -SO_2-NR^8R^9,

R^7 is -F, -OH, -O-(C_1-C_{10})-alkyl, -O-phenyl, -O-CO-(C_1-C_{10})-alkyl, O-CO-O-aryl, O-CO-O-heteroaryl, -NR^8R^9, oxo, phenyl, -CO-(C_1-C_5)-alkyl, -CF_3, -CN, -$CONR^8R^9$, -COOH, -CO-O-(C_1-C_5)-alkyl, -CO-O-aryl, -$S(O)_n$-(C_1-C_5)-alkyl, -SO_2-NR^8R^9,

R^8 is hydrogen or C_1-C_{20}-alkyl, and

R^9 is hydrogen, C_1-C_{20}-alkyl, aryl, or heteroaryl,

wherein aryl groups are carbocyclic aryl groups,

wherein heteroaryl groups are 5- to 7-membered unsaturated heterocycles comprising 1-4 heteroatoms chosen from O, N, and S,

or a physiologically acceptable salt, hydrate, or ester thereof, in any stereoisomeric or tautomeric form.

2. (Currently Amended) The compound of the formula (Ia) as claimed in claim 1, in which

R^1 is hydrogen, (C_1-C_{10})-alkyl, (C_3-C_8)-cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, (C_1-C_3)-alkylaryl, (C_1-C_3)-alkylheteroaryl, arylalkyl, or heteroarylalkyl, wherein R^1 is unsubstituted or the alkyl radicals are substituted with at least one substituent chosen from R^6,

R^2 is (C_1-C_{10})-alkyl, (C_3-C_8)-cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, (C_1-C_3)-alkylaryl, or (C_1-C_3)-alkylheteroaryl wherein R^2 is unsubstituted or the alkyl radicals are substituted with at least one substituent chosen from R^6,

or R^1 and R^2 may, together with the nitrogen atom bearing them, form a 3-8-membered ring, wherein said 3-8-membered ring optionally comprises 0, 1 or 2 further heteroatoms chosen from N, O, and S and wherein said 3-8-membered ring is unsubstituted or substituted by at least one substituent chosen from R^6,

R^3 is hydrogen, -CO-(C_1-C_7)-alkyl, -CO-(C_1-C_3)-alkylaryl, -CO-(C_1-C_3)-alkylheteroaryl, -CO-aryl, or -CO-heteroaryl,

R^4 is (C_1-C_{10})-alkyl, aryl, heteroaryl, (C_1-C_3)-alkylaryl, (C_1-C_3)-alkylheteroaryl -CO-O-(C_1-C_5)-alkyl, -CO-O-aryl, -CO-O-heteroaryl, -CO-(C_1-C_5)-alkyl, -CO-aryl or -CO-heteroaryl, wherein R4 is unsubstituted or the alkyl radicals are substituted with at least one substituent chosen from R^7,

R^5 is hydrogen, CO-(C_1-C_7)-alkyl, -CO-(C_1-C_3)-alkylaryl, -CO-(C_1-C_3)-alkylheteroaryl, -CO-aryl, or -CO-heteroaryl,

R^6 is -F, -OH, -O-(C_1-C_{10})-alkyl, -O-phenyl, -O-CO-(C_1-C_{10})-alkyl, -O-CO-aryl, -O-CO-heteroaryl, -NR^8R^9, oxo, phenyl, -CO-(C_1-C_5)-alkyl, -CF_3, -CN, -$CONR^8R^9$, -COOH, -CO-O-(C_1-C_5)-alkyl, -CO-O-aryl, -CO-O-heteroaryl, -$S(O)_n$-(C_1-C_5)-alkyl, -SO_2-NR^8R^9,

R^7 is -F, -OH, -O-(C_1-C_{10})-alkyl, -O-phenyl, -O-CO-(C_1-C_{10})-alkyl, -O-CO-aryl, O-CO-heteroaryl, -NR^8R^9, oxo, phenyl, -CO-(C_1-C_5)-alkyl, -CF_3, -CN, -$CONR^8R^9$, -COOH, -CO-O-(C_1-C_5)-alkyl, -CO-O-aryl, -CO-O-heteroaryl, -$S(O)_n$-(C_1-C_5)-alkyl, -SO_2-NR^8R^9,

R^8 is hydrogen or (C_1-C_5)-alkyl, and

R^9 is hydrogen, (C_1-C_5)-alkyl or phenyl,

wherein each aryl group is phenyl or naphthyl, and
wherein said heteroaryl groups are 5- to 7-membered unsaturated heterocycles comprising 1-4 heteroatoms chosen from O, N, and S,

wherein said phenyl, naphthyl and heteroaryl groups are substituted groups which are substituted by at least one substituent chosen from halogen, (C_1-C_5)-alkyl or phenyl, -OH, -O-(C_1-C_5)-alkyl, (C_1-C_2)-alkylenedioxy, -N^8R^9, -NO_2, -CO-(C_1-C_5)-alkyl, -CF_3, -CN, -$CONR^8R^9$, -COOH, -CO-O-(C_1-C_5)-alkyl, -$S(O)_n$-(C_1-C_5)-alkyl, -SO_2-NR^8R^9,

wherein n is 0, 1 or 2,

or a physiologically acceptable salt, hydrate, or ester thereof, in any stereoisomeric or tautomeric form.

3. (Currently Amended) A compound of the formula (Ia) as claimed in claim 1, in which

R^1 is hydrogen, unsubstituted (C_2-C_4)-alkyl, substituted (C_2-C_4)-alkyl which is substituted by at least one R^6, or (C_1-C_2)-alkyl aryl or (C_1-C_2)-alkylheteroaryl,

R^2 is unsubstituted (C_2-C_4)-alkyl, substituted (C_2-C_4)-alkyl which is substituted by at least one R^6, or cyclohexylmethyl or (C_1-C_2)-alkylaryl or (C_1-C_2)-alkylheteroaryl,

or R^1 and R^2, together with the nitrogen atom bearing them, form a 5-7-membered ring wherein said 5-7-membered ring optionally comprises an additional heteroatom chosen from N, O, and S,

R^3 is hydrogen, -CO-(C_1-C_3)-alkyl, -CO-aryl or -CO-heteroaryl,

R^4 is aryl, heteroaryl, (C_1-C_5)-alkyl, -CO-O-aryl or -CO-heteroaryl, wherein R^4 is unsubstituted or substituted with at least one substituent chosen from R^7,

R^5 is hydrogen,

R^6 is -OH, -O-(C_1-C_3)-alkyl, -NR^8R^9 or -COOH, and

R^7 is -OH, (C_1-C_{10})-alkyloxy, phenoxy or oxo,

wherein each aryl group is phenyl,

wherein said heteroaryl groups are chosen from thiophenyl, furyl and pyridyl,

wherein said phenyl, thiophenyl, furyl or pyridyl groups are unsubstituted groups or substituted groups which are substituted by at least one substituent chosen from (C_1-C_3)-alkyl, halogen, (C_1-C_3)-alkyloxy and (C_1-C_2)-alkylenedioxy, and

or a physiologically acceptable salt, hydrate, or ester thereof, in any stereoisomeric or tautomeric form.

4. (Currently Amended) A compound of the formula (Ia) as claimed in claim 1, in which

R^1 is arylmethyl,

R^2 is arylmethyl or cyclohexylmethyl,

or R^1 and R^2, together with the nitrogen atom bearing them, form a pyrrolidine, piperidine, morpholine, dimethylmorpholine, thiomorpholine, or N-(C_1-C_2)-alkylpiperazine ring,

R^3 is hydrogen,

R^4 is arlkyl or 1,2-dihydroxypropyl,

R^5 is hydrogen,

R^6 is -OH, -O-(C_1-C_3)-alkyl, -NR^8R^9 or -COOH, and

R^7 is -OH, decyloxy or phenoxy,

wherein each aryl group is chosen from unsubstituted phenyl or substituted phenyl, which is substituted by at least one substituent chosen from (C_1-C_3)-alkyl, halogen and (C_1-C_3)-alkyloxy and (C_1-C_2)-alkylenedioxy,

or a physiologically acceptable salt, hydrate, or ester thereof, in any stereoisomeric or tautomeric form.

5. (Currently Amended) The compound of formula (Ia) as claimed in claim 1, which is a tetrahydropteridine wherein R^4 is aryl, heteroaryl, $(C_1$-$C_5)$-alkyl -CO-O-aryl or -CO-O-(heteroaryl), and wherein said R^4 is unsubstituted or substituted with at least one substituent chosen from R^7.

6. (Currently Amended) The compound of formula (Ia) as claimed in claim 1, ~~which is a pteridine~~ wherein

R^1 and R^2 are each, independently alkyl aryl, or heteroaryl, or

R^1 is hydrogen and R^2 is cycloalkyl or cycloalkylalkyl, and

wherein R^4 is aryl, $(C_1$-$C_5)$-alkyl -CO-O-aryl or -CO-O-(heteroaryl), wherein said R^4 is unsubstituted or substituted with at least one substituent chosen from R^7.

7. (Currently Amended) A pharmaceutical comprising a compound of formula (Ia), (Ib), or (Ic) as claimed in claim 1 and an additional ingredient chosen from conventional excipients and additives.

8. (Previously Amended) A method of treating or preventing strokes comprising administration of at least one pharmaceutical of claim 7 to a patient in need thereof.

9. (Cancelled)

10. (Cancelled)

11. (Currently Amended) A process for preparing ~~the~~ a compound of formula (Ia), (Ib), or (Ic) as claimed in claim 1 comprising reacting a compound of the formula II



(II)

with a compound of the formula III

$$HNR^1R^2 \qquad \text{(III)}$$

which results in a compound of the formula IV



(IV)

wherein the compound of formula IV is converted to a compound of formula V by catalytic hydrogenation



(V)

and wherein a compound of formula V is reacted with a compound of the formula VI



(VI)

to give a compound of formula (Ia), (Ib), or (Ic).

12 - 14. (Cancelled).